AVR RD 06
Alternative Names: AVR-RD-06Latest Information Update: 25 Jun 2024
At a glance
- Originator Lund University
- Developer Tectonic Therapeutic
- Class Gene therapies; Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Gaucher's disease type III
Most Recent Events
- 20 Jun 2024 AVROBIO has been merged with Tectonic Therapeutic to form Tectonic Therapeutic
- 12 Jul 2023 Suspended - Preclinical for Gaucher's disease type III in USA (Parenteral) as AVROBIO is exploring strategic alternatives
- 09 Aug 2022 AVROBIO plans to engage with regulatory agencies on a phase II/III clinical development strategy in Gaucher's disease type III